Influenza, commonly called the flu, is caused by a virus, not a bacterium or any other type of pathogen. Specifically, it belongs to the family Orthomyxoviridae and comes in four distinct types, each with different host ranges, severity profiles, and public health significance. The distinction matters more than it might seem, because the viral nature of influenza shapes everything from how it spreads to why antibiotics do nothing against it and why you need a new vaccine almost every year.
The Four Types of Influenza Virus
There are four recognized types of influenza virus, labeled A through D. They differ in who they infect, how much disease they cause, and how much attention public health agencies give them.
- Influenza A: The most dangerous and versatile type. It infects a wide variety of birds and mammals, including humans, and is the only type responsible for major pandemics. Its surface proteins change rapidly, which is why new strains can catch populations off guard.
- Influenza B: Primarily a human virus. It causes seasonal epidemics that range in severity and contributes substantially to the flu burden each winter, though it does not spark pandemics.
- Influenza C: Infects humans and pigs but typically causes only mild or symptom-free infections. You are unlikely to hear much about it because it rarely causes significant illness.
- Influenza D: Mainly affects cattle and swine. No confirmed cases of human infection or disease have been documented.
When people talk about “the flu,” they almost always mean influenza A or B. These two types are responsible for the seasonal epidemics that fill hospitals and urgent care clinics every winter, and they are the targets of annual flu vaccines.1PubMed Central. Influenza B, C and D Viruses (Orthomyxoviridae)
What Makes Influenza a Virus, Not a Bacterium
Bacteria are single-celled organisms that can survive and reproduce on their own. Viruses cannot. Influenza viruses are tiny packets of genetic material wrapped in a protein coat, and they are completely dependent on a living host cell to copy themselves. Influenza A, for instance, carries its genetic information as eight separate segments of RNA, each wrapped with proteins into a compact structure that serves as the basic unit for copying and reading the viral genes.2PubMed Central. Structure of influenza virus ribonucleoprotein complexes and their packaging into virions
One unusual feature of influenza is that it copies itself inside the nucleus of the host cell, unlike most RNA viruses, which replicate in the cell’s main compartment. This gives influenza access to the cell’s own machinery, but it also means the virus has to navigate a complicated route in and out of the nucleus to complete its life cycle.3PubMed Central. Influenza A Virus Cell Entry, Replication, Virion Assembly and Movement The practical takeaway for you is simple: because influenza is a virus, antibiotics are useless against it. Antibiotics target bacteria. Treating flu requires antiviral medications or, better yet, prevention through vaccination.
Why the Flu Virus Keeps Changing
One reason influenza remains a persistent threat is that it evolves constantly. Its surface proteins, the parts your immune system recognizes and targets, change through two main processes. The first is a gradual accumulation of small mutations, which subtly alter the virus’s appearance to your immune system over time. The second is a more dramatic reshuffling that happens when two different influenza A strains infect the same cell and swap entire gene segments, producing a substantially new virus. This second process is what sets the stage for pandemics.4PubMed. Influenza Virus: Dealing with a Drifting and Shifting Pathogen
The gradual mutation process is the reason flu vaccine formulas are reviewed and often updated before every flu season. Laboratories around the world that contribute to the World Health Organization’s surveillance network track how circulating viruses are changing throughout the year. Vaccine strains are chosen months in advance to allow time for manufacturing, but this lead time means the selected strains sometimes end up mismatched with whatever ends up dominating when flu season actually arrives.5PubMed Central. Models for predicting the evolution of influenza to inform vaccine strain selection That mismatch is a well-known limitation, and researchers are actively developing computational tools to forecast viral evolution more accurately.6PubMed Central. Predictive evolutionary modelling for influenza virus by site-based dynamics of mutations
How Flu Spreads From Person to Person
Influenza can spread through three main routes: direct contact with contaminated surfaces or secretions, larger respiratory droplets expelled by coughing or sneezing, and smaller airborne particles called aerosols that can linger in the air.7Emerging Infectious Diseases. Review of Aerosol Transmission of Influenza A Virus Research has confirmed that aerosol transmission is a meaningful route, not just a theoretical one.8PubMed Central. Aerosol transmission is an important mode of influenza A virus spread The relative contribution of each route is still debated, but the practical implication is that simply staying out of sneezing range is not a guarantee of safety in a shared indoor space.
Timing also matters. An infected person can shed virus before symptoms even start, and children are especially concerning in this regard. A household transmission study in Nicaragua found that children under six shed virus for longer both before and after symptoms appeared compared to adults.9PubMed Central. The Timeline of Influenza Virus Shedding in Children and Adults in a Household Transmission Study of Influenza in Managua, Nicaragua This partly explains why young children are such effective spreaders of flu within families and schools. A separate study of household transmission found that the relationship between viral load and infectiousness is not straightforward; a person’s ability to transmit the virus does not simply track with how much virus they are shedding at any given moment.10PubMed Central. Influenza A Virus Shedding and Infectivity in Households
Why Flu Hits Hardest in Winter
If you live in a temperate climate, flu season and cold weather feel inseparable. That is not a coincidence. Experimental work has shown that influenza transmission is strongly affected by temperature and humidity. Cold, dry conditions favor the virus: it survives longer on surfaces and in the air, and the droplets it rides in evaporate into smaller, more easily inhaled particles.11PubMed Central. Roles of humidity and temperature in shaping influenza seasonality Both low absolute humidity and low temperature are associated with higher rates of influenza A and B infections, though the relationship is nonlinear and differs somewhat between the two virus types.12PubMed Central. Effects of Absolute Humidity, Relative Humidity, Temperature, and Wind Speed on Influenza Activity in Toronto, Ontario, Canada
Indoor crowding during cold months likely contributes too, but the environmental physics of the virus itself appear to be a major driver. In tropical climates, flu does not follow the same tidy winter pattern, which is part of why these regions sometimes see year-round transmission instead.
Symptoms and What Actually Causes Them
The classic flu hits fast: fever, muscle aches, headache, fatigue, cough, and sometimes sore throat or congestion. What most people do not realize is that the virus itself is not directly responsible for most of those symptoms. Your immune system is. When influenza infects the cells lining your respiratory tract, your body mounts an inflammatory response, flooding the area with signaling molecules called cytokines. Research on naturally acquired influenza A found that a specific cytokine, IL-6, was released in large quantities in both the nasal passages and the bloodstream. IL-6 levels correlated with both the severity of symptoms and fever.13PubMed. Symptom pathogenesis during acute influenza: interleukin-6 and other cytokine responses
This is why you can feel terrible even as your body is successfully fighting off the virus. The aches, the fever, the exhaustion: these are side effects of an immune system working at full intensity. In most healthy adults, the immune response clears the virus within a week or so. But in some people, the response either overshoots or the damage it causes opens the door to secondary problems.
Complications That Make Flu Dangerous
For the average healthy adult, flu is miserable but self-limiting. The danger lies in complications, and the most common serious one is secondary bacterial pneumonia. When influenza damages the lining of the respiratory tract, it creates an environment where bacteria that normally live harmlessly in the nose and throat can invade the lungs. This can happen in two ways: as a combined viral-bacterial infection during the acute illness, or as a post-influenza pneumonia that develops after the initial viral symptoms have started to improve.14PubMed Central. Bench-to-bedside review: bacterial pneumonia with influenza – pathogenesis and clinical implications The second type is particularly insidious because the body’s effort to repair the damage from the virus temporarily weakens its defenses against bacteria.15PubMed Central. Postviral Complications: Bacterial Pneumonia
Beyond pneumonia, influenza can affect the heart. Acute myocarditis, or inflammation of the heart muscle, is a recognized complication. The severity ranges from cases so mild they go unnoticed to rare fulminant forms that can be fatal due to impaired heart function.16PubMed Central. Myocarditis Associated with Influenza A H1N1pdm2009 Other complications include worsening of chronic lung conditions like asthma and COPD, kidney injury, and neurological events such as encephalitis, though these are less common. The sheer volume of people who catch flu every year means that even relatively rare complications add up to a significant burden.
Who Faces the Greatest Risk
Flu does not hit everyone equally. Age is the single biggest risk factor for ending up in the hospital. A large analysis of over 1.6 million influenza cases in the United States found that people aged 65 and older had roughly nine times the odds of hospitalization compared to school-age children. Certain chronic conditions doubled or tripled those odds further.17PubMed Central. Burden of influenza hospitalization among high-risk groups in the United States Among elderly patients with existing health problems, the hospitalization rates were striking: more than four in ten flu patients with congestive heart failure and roughly the same proportion of those with late-stage kidney disease were hospitalized within 30 days, compared to single-digit rates in similar patients without flu.17PubMed Central. Burden of influenza hospitalization among high-risk groups in the United States
Hospital data tells a similar story: patients with confirmed influenza infections had a significantly higher risk of death than other patients, and the highest death risk was among those hospitalized for cardiac, lung, and kidney conditions.18PubMed Central. Influenza as an important factor causing increased risk of patients’ deaths, excessive morbidity and prolonged hospital stays During the 2009 H1N1 pandemic, a global analysis found that the proportion of patients with at least one chronic condition increased with severity: roughly a third of hospitalized cases, about half of ICU admissions, and about six in ten fatal cases had a pre-existing condition. Pregnancy (especially in the third trimester) and morbid obesity also stood out as risk factors for severe outcomes.19PLoS Medicine. Risk Factors for Severe Outcomes following 2009 Influenza A (H1N1) Infection: A Global Pooled Analysis
How Flu Is Diagnosed
If you go to a clinic with flu symptoms, you might get a rapid antigen test, which gives results in minutes. These tests are convenient but far from perfect. A large systematic review found that traditional rapid tests detected only about half of influenza A cases and a similar proportion of influenza B cases. Newer digital immunoassays performed better, catching around 80% of influenza A infections. The gold standard, molecular testing using nucleic acid amplification, caught over 90% of both A and B cases. All these tests were highly specific, meaning a positive result is almost certainly real, but a negative result from a rapid test does not reliably rule flu out.20PubMed. Diagnostic Accuracy of Novel and Traditional Rapid Tests for Influenza Infection Compared With Reverse Transcriptase Polymerase Chain Reactionp>
Where the sample is taken matters, too. One evaluation found that rapid antigen tests performed on nasal swabs caught about 59% of cases, while the same test performed on throat swabs caught only about 10%.21PubMed Central. Performance evaluation of influenza a rapid antigen test and PCR among nasopharyngeal and oropharyngeal samples Timing affects accuracy as well. A large real-world study in China found that rapid antigen tests performed better in the early days of illness (within the first two days of symptoms), while molecular tests peaked in accuracy slightly later, around days one through three.22PubMed. Comparative study of rapid influenza antigen tests versus PCR in an influenza-like illness population: A real-world multicenter study in China If you test negative on a rapid test but still feel strongly that you have the flu, asking for a molecular test or retesting a day later is reasonable.
Treatment With Antiviral Drugs
Because influenza is a virus, the treatments that work against it are antivirals, not antibiotics. Several antiviral drugs are currently recommended for treating influenza A and B, and they work through different mechanisms. The older class, neuraminidase inhibitors like oseltamivir (sold as Tamiflu), block a protein the virus needs to release newly made copies from infected cells. A newer drug, baloxavir marboxil, works differently by blocking the virus’s ability to copy its own genes. Research comparing these options suggests that baloxavir has a similar safety and effectiveness profile to the established neuraminidase inhibitors.23PubMed Central. Antiviral Drugs in Influenza
The catch with all flu antivirals is timing. They work best when started within the first 48 hours of symptoms, which is why getting tested early matters. After that window, the drugs still have some benefit in high-risk patients, but the effect shrinks. For most healthy adults with uncomplicated flu, antiviral treatment shortens illness by roughly a day. The greater value is in preventing progression to severe disease in people who are elderly, pregnant, immunocompromised, or have chronic heart or lung problems.
Vaccines and the Annual Guessing Game
The annual flu vaccine remains the most effective tool for preventing influenza, but its effectiveness varies from year to year for reasons that go back to the virus’s relentless evolution. Vaccine composition is decided months before each flu season by expert committees who analyze surveillance data on circulating strains. This process works well in some years and poorly in others, because the virus does not pause its evolution during the months of vaccine manufacturing.5PubMed Central. Models for predicting the evolution of influenza to inform vaccine strain selection
Researchers are trying to remove some of the guesswork. Computational models that simulate how influenza’s surface proteins are likely to change can help predict which strains will dominate in the coming season, potentially improving vaccine-to-circulating-virus matches.6PubMed Central. Predictive evolutionary modelling for influenza virus by site-based dynamics of mutations More recently, artificial intelligence models that integrate evolutionary dynamics with antigenic data have been developed to rank candidate vaccine strains by their predicted coverage against the viruses expected to circulate.24Nature Medicine. Influenza vaccine strain selection with an AI-based evolutionary and antigenicity model These approaches are still relatively new, but they represent a shift from relying purely on laboratory observation toward data-driven forecasting. Even a modest improvement in strain matching could prevent thousands of hospitalizations in a typical flu season.
The long-term goal for the field is a universal flu vaccine, one that targets the parts of the virus that do not change much from year to year. Several candidates are in clinical trials, but none has reached the market yet. Until then, the annual shot, imperfect as it is, still reduces your chances of getting flu and substantially reduces the risk of ending up in the hospital if you do.
The Pandemic Question and Avian Flu
Seasonal flu is a known quantity. Pandemic flu is the wild card, and it is always influenza A that poses the threat. Pandemics arise when a virus with surface proteins that most humans have never encountered begins spreading efficiently between people. The 20th century saw several such events, and the question is not whether another will happen but when.
Right now, the most-watched candidate is highly pathogenic avian influenza, particularly the H5N1 subtype. H5N1 circulates widely in bird populations and occasionally jumps to mammals, including humans, through direct contact with infected animals. Modeling research identifies South and Southeast Asia as likely locations for an initial outbreak, given the density of poultry farming and close human-animal contact in those regions. A pandemic scenario would begin with isolated bird-to-human infections followed by the virus acquiring the ability to spread efficiently from person to person.25PubMed Central. Modelling a potential zoonotic spillover event of H5N1 influenza That second step has not yet happened with H5N1, which is why it remains a threat rather than a crisis. But surveillance efforts remain intense precisely because the consequences of missing the early stages of such a transition would be severe.
The segmented genome of influenza A is what makes this scenario biologically plausible. If a bird flu virus and a human flu virus infect the same host simultaneously, they can swap gene segments and produce a hybrid that combines the novel surface proteins of the bird virus with the transmissibility traits of the human virus. This kind of genetic reassortment is what generated past pandemic strains, and it is the reason public health agencies track avian influenza in animal populations with such urgency.4PubMed. Influenza Virus: Dealing with a Drifting and Shifting Pathogen